AI Article Synopsis
Article Abstract
Aim: To study efficacy of ursodesoxycholic acid (UA) drugs in the treatment of polypous and polyporeticular cholesterosis of the gallbladder (CGB), including combination with biliary sludge, with reference to terms of the treatment.
Material And Methods: A contraction function of the gallbladder was studied ultrasonically in 74 CGB patients treated with UA drugs. The treatment lasted from 1 month to 1.5 years. A response (complete or partial dilution of cholesterol polyps) was recorded in 71.6% patients. Therapy was less effective if the gallbladder contained biliary sludge, heterogeneous bile and suspension, dense bile. The lytic therapy effect improved with treatment duration. Complete dissolving of cholesterol polyps was achieved after at least 10-month treatment. The treatment also brought about a marked choleretic effect and an increased ejection fraction of the gallbladder.
Conclusion: UA drugs can be used in the treatment of CGB.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Efficacy of wound care ointment in healing infectious wounds after anorectal surgery: A randomized controlled trial.
Medicine (Baltimore)
January 2025
Anorectal Department, People's Hospital of Leshan, Leshan, Sichuan, China.
Background: This study evaluates the efficacy of a novel bismuth subgallate-borneol compound ointment as an adjuvant therapy in promoting postoperative healing of infectious incisions after anorectal surgery.
Methods: From June 2023 to October 2023, 46 patients with perianal abscess and anal fistula treated at our institution's Anorectal Surgery Department were enrolled in this prospective randomized controlled study. Patients were randomly allocated into 2 groups: the experimental group (n = 23) received conventional wound care plus a proprietary ointment containing 4.
Machine Learning to Predict Mortality in Older Patients With Cancer: Development and External Validation of the Geriatric Cancer Scoring System Using Two Large French Cohorts.
J Clin Oncol
January 2025
INSERM, IMRBU955, Univ Paris Est Créteil, Créteil, France.
Purpose: Establishing an accurate prognosis remains challenging in older patients with cancer because of the population's heterogeneity and the current predictive models' reduced ability to capture the complex interactions between oncologic and geriatric predictors. We aim to develop and externally validate a new predictive score (the Geriatric Cancer Scoring System [GCSS]) to refine individualized prognosis for older patients with cancer during the first year after a geriatric assessment (GA).
Materials And Methods: Data were collected from two French prospective multicenter cohorts of patients with cancer 70 years and older, referred for GA: ELCAPA (training set January 2007-March 2016) and ONCODAGE (validation set August 2008-March 2010).
Treatment of refractory poly articular course juvenile idiopathic arthritis with tofacitinib: Extended experience from Bangladesh.
PLoS One
January 2025
Department of Pediatrics, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka, Bangladesh.
Background: Juvenile Idiopathic arthritis (JIA) is one of the most common chronic diseases in children. It still remains a challenge to treat refractory poly-articular course JIA patients, especially in Bangladesh, where patients from low socio-economic backgrounds are unable to manage biological agents. Tofacitinib is one of the alternative options to biological agents, which can be taken orally and is cost effective.
View Article and Find Full Text PDFStructure-guided identification of mitogen-activated protein kinase-1 inhibitors towards anticancer therapeutics.
PLoS One
January 2025
Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India.
Mitogen-activated protein kinase 1 (MAPK1) is a serine/threonine kinase that plays a crucial role in the MAP kinase signaling transduction pathway. This pathway plays a crucial role in various cellular processes, including cell proliferation, differentiation, adhesion, migration, and survival. Besides, many chemotherapeutic drugs targeting the MAPK pathway are used in clinical practice, and novel inhibitors of MAPK1 with improved specificity and efficacy are required.
View Article and Find Full Text PDFStructure-guided engineering of a mutation-tolerant inhibitor peptide against variable SARS-CoV-2 spikes.
Proc Natl Acad Sci U S A
January 2025
Cellular and Structural Physiology Laboratory, Advanced Research Initiative, Institute of Integrated Research, Institute of Science Tokyo, Bunkyo-ku, Tokyo 113-8510, Japan.
Pathogen mutations present an inevitable and challenging problem for therapeutics and the development of mutation-tolerant anti-infective drugs to strengthen global health and combat evolving pathogens is urgently needed. While spike proteins on viral surfaces are attractive targets for preventing viral entry, they mutate frequently, making it difficult to develop effective therapeutics. Here, we used a structure-guided strategy to engineer an inhibitor peptide against the SARS-CoV-2 spike, called CeSPIACE, with mutation-tolerant and potent binding ability against all variants to enhance affinity for the invariant architecture of the receptor-binding domain (RBD).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!